Abstract
Objective: To evaluate the 24-hour efficacy of tafluprost on the reduction of intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). Methods: In this case-series study, a total of 43 eyes of 22 newly diagnosed patients with POAG and OHT from Shengyang Aier Eye Hospital were enrolled. All patients were trained to use an Icare HOME tonometer to measure IOP by themselves. For the certificated patients, aphysician used GAT to measure their IOP three times, and then the patients used Icare HOME to measure 24-hour IOP by themselves. Patients was given tafluprost once a day at 21∶00. Icare HOME was used by the patients themselves to measure 24-hour IOP again one month later. A one-way ANOVA and Bland-Altman analysis were used to compare the consistency of the GAT used by a physician and the Icare HOME used by patients to measure IOP. A paired t test was used to compare IOP at each time point, the mean, the peak, the valley and the fluctuation of 24-hour IOP before and after treatment with tafluprost. Results: The mean IOPs measured with GAT by a physician and Icare HOME by patients were 18.2±3.7 mmHg (1 mmHg=0.133 kPa) and 17.4±4.2 mmHg, respectively, with no statistically significant difference (F=0.837, P=0.363). Bland-Altman analysis showed that there was a good consistency between GAT measured by a physician and Icare HOME measured by patients. IOP decreased at all time points of assessment after 1 month (all P<0.05). The range of IOP reduction at different time points was 1.8 to 5.5 mmHg (all P<0.05). The mean, the peak, the valley, and the fluctuation of IOP at baseline were 19.4±5.0, 25.0±5.8, 14.1±4.5 and 10.9±3.8 mmHg, respectively, and were reduced to 15.6±4.2, 20.4±4.5, 11.3±3.6 and 9.2±2.9 mmHg after treatment (t=9.450, 9.636, 5.939, 3.137, all P<0.05). Conclusions: Tafluprost provides effective 24-hour IOP reduction in newly diagnosed patients with POAG and OHT. Key words: glaucoma, open-angle; ocular hypertension; tonometry, ocular; tafluprost
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.